A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Trial Profile

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs RPC 4046 (Primary) ; RPC 4046 (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HEROES
  • Sponsors Celgene Corporation; Receptos
  • Most Recent Events

    • 08 May 2017 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2016 Results assessing global assessment of disease severity and safety presented at the 24th United European Gastroenterology Week.
    • 13 Oct 2016 According to a Celgene Corporation media release, data from this trial will be presented at the United European Gastroenterology (UEG) Week and the American College of Gastroenterology (ACG) Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top